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Abstract
Using a questionnaire, we assessed the current status of the quality management systems at HIV screening laboratories in Korea. The
Korea Centres for Disease Control and Prevention HIV external quality assurance scheme (EQAS) questionnaire includes 18 items
divided into five groups related to HIV testing: personnel, HIV test processes, participation in the Quality Assurance programme and
HIV testing equipment. Five hundred and sixty-one HIV screening laboratories participated in this questionnaire investigation; data were
collected from 233 public health centres, 309 hospitals or clinics, eight blood centres and 11 commercial laboratories. The total number
of HIV screening tests was about 5.5 million in 2005. The average number of HIV tests per institution was highest in blood centres
(308 561), followed by commercial laboratories (56 084), hospital or clinic laboratories (6756), and public health centres (1751). Equip-
ment and HIV test methods varied between HIV screening laboratories, and, to manage the quality of their HIV testing, most laborato-
ries participated in several evaluation programmes such as EQAS or a laboratory accreditation programme. This study is the first
questionnaire survey of HIV testing laboratories in Korea. The results could be used to evaluate and promote the quality management
of HIV testing laboratories.
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Introduction
Since the US Food and Drug Administration approved ELISA
diagnosis kits for donor screening in 1985 [1], various types
of test kits and equipment have been developed for detecting
and quantifying HIV and adopted according to each labora-
tory’s conditions and requirements. These HIV test methods
have been developed rapidly compared with other diagnostic
testing kits. Screening tests have been conducted for high-
risk groups in Korea since the first case of HIV infection was
identified in 1985 [2]. Blood centres have tested all donated
blood since 1987, and public health centres have tested all
blood since 1992 [3,4]. The number of HIV screening tests
conducted at hospitals or clinics has been increasing
gradually, and five to six million tests are estimated to be
performed each year in Korea. The number of HIV cases has
also increased gradually, and the accumulated number up to
2006 stands at 4580 [5].
Until 2005, the HIV testing strategy in Korea was a three-
step process, in which positive results at public health cen-
tres, private medical centres such as hospitals or clinics, and
blood centres (which collect and test blood for donations)
were checked by the Local Institutes of Public Health and
Environment (LIHEs) for public health centres and hospitals
and the Blood Transfusion Research Institute (BTRI) for
blood centres and finally confirmed by the Korea Centres
for Disease Control and Prevention (KCDC). This was
reduced to two steps from 2006 by empowering LIHEs to
make the final decision on HIV test results [6].
The reliability of an HIV test result is essential because of
the implications for the individual and for society. HIV testing
laboratories are actively involved in the HIV external quality
assurance scheme (EQAS), begun in 1989 [7], which provides
the opportunity to review every stage of the testing process:
receiving samples, analysis, laboratory testing strategies,
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and reporting of test results. By comparing results between
laboratories, EQAS shares information on diagnostic kits and
laboratory environments, and allows the laboratories them-
selves to assess their procedures. Because HIV prevalence is
relatively low [8], HIV-positive results are rare in Korean lab-
oratories. Therefore, laboratories can improve their testing
skills and abilities by participating in the EQAS programme
for testing various samples for anti-HIV or antigen titre.
From 2005, 620 public and private HIV testing laboratories
have participated in EQAS programmes twice a year [6].
This study analysed the results of a survey that partici-
pants completed during a 2006 HIV EQAS programme,
to assess the current state of HIV testing laboratories. In
addition, it can provide reference data for future EQAS
programmes and development of a national HIV testing
policy in Korea.
Materials and Methods
Data collection and participating laboratories
The survey included 615 HIV laboratories that participated
in the 2006 HIV EQAS Programme. The survey was
conducted from 12 June to 14 July and was co-sponsored by
the KCDC and the Korean Society for Laboratory Medicine
(KSLM). The survey was conducted online through the HIV
laboratory quality assurance website (http://hivqa.nih.go.kr).
Responses were received from 561 out of 583 screening lab-
oratories: 233 public health centres, 309 hospitals or clinics,
eight blood centres and 11 commercial laboratories. Four
HIV counselling services, 17 LIHEs and one BTRI were
excluded because this study was aimed at primary HIV test-
ing laboratories.
Questionnaire survey
The survey asked questions about five main HIV-related top-
ics: (i) the number of HIV tests, methods and positivity rate;
(ii) the status, training and experience of the personnel in
charge of the HIV testing and their participation in the qual-
ity assurance (QA) programme; (iii) HIV testing equipment,
automation and monitoring; (iv) practicalities of HIV testing
procedures, including retesting of positive and borderline
results, external confirmation of positive results, and report-
ing results; and (v) internal quality control (IQC).
Results
The number of HIV tests and methods
The average number of HIV screening tests per year and the
testing methods of each laboratory are shown in Table 1.
The average annual number of HIV tests was 308 561 at
blood centres, 56 056 at commercial laboratories, 6756 at
hospitals or clinics, and 1751 at public health centres. Each
laboratory adopted a testing method suitable to its particular
conditions. The highest rate of HIV-positive results came
from hospitals or clinics, at 0.22%.
The personnel in charge of the HIV testing and
participation in the QA programme
Nearly all (99.1%) of those in charge of HIV testing in the
laboratories were medical technologists. In public health cen-
tres they had an average of 7.7 years of experience, which
was greater than that seen in the other organizations. The
average job rotation duration was longest at public health
centres (4.1 years). More than half of all staff at public health
centres participated in HIV-related training (education). Also,
57.9% of all HIV laboratories participated in the EQAS Pro-
gramme of the Korean Association of Quality Assurance of
Clinical Laboratories, while 43.3% of all HIV laboratories par-
ticipated in the laboratory certification programme of the
KSLM. Ten laboratories were enrolled in the College of
American Pathology, eight in the ISO 9002, and one in the
ISO 9000 certification programmes (Table 2).
TABLE 1. Average number of HIV tests and preliminary results according to the test method used in HIV screening
laboratories in 2005
Test
method
Public health centres Hospital or clinic laboratories Blood centres Commercial laboratories
No.
laboratories
(%)a
Average
no. HIV
testsb
Preliminary
positive %
(mean ± SD)c
No.
laboratories
(%)a
Average
no. HIV
testsb
Preliminary
positive %
(mean ± SD)c
No.
laboratories
(%)a
Average
no. HIV
testsb
Preliminary
positive %
(mean ± SD)c
No.
laboratories
(%)a
Average
no. HIV
testsb
Preliminary
positive %
(mean ± SD)c
Total 233 1751 0.16 ± 0.70 309 6756 0.22 ± 1.56 8 308 561 0.09 ± 0.04 11 56 056 0.04 ± 0.03
ELISA 147 (63) 1990 0.21 ± 0.86 235 (76) 8434 0.24 ± 1.76 8 (100) 308 561 0.09 ± 0.04 10 (90) 60 462 0.04 ± 0.09
PA 56 (24) 1422 0.04 ± 0.08 9 (3) 2481 0.21 ± 0.43 – – – – – –
RT 30 (13) 1193 0.13 ± 0.37 65 (21) 1283 0.14 ± 0.48 – – – 1 (10) 12 000 0.01 ± 0.00
PA, particle agglutination test; RT, rapid test.
aNo. labs (%): the number of laboratories (percentage).
bAverage no. HIV tests: the average number of HIV tests performed by each laboratory in 2005.
cPreliminary positive % (mean ± SD): the percentage of positive results for HIV screening tests per year.
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HIV testing equipment
Table 3 shows the percentage of laboratories that used auto-
mated equipment: 90.9% of commercial laboratories, 75.1%
of hospitals or clinics, 47.6% of public health centres, and
12.5% of blood centres. New equipment was purchased in
the preceding 5 years by 72.7% of commercial laboratories,
53.7% of hospitals or clinics, 50% of blood centres, and
32.2% of public health centres. Testing equipment was not
used in 31.8% of public health centres, 22.7% of hospitals or
clinics, and 9.1% of commercial laboratories; these laborato-
ries used the rapid test (RT) or particle agglutination (PA)
assays.
Equipment was checked most often after failure in use.
Regular equipment check-ups were performed at least three
times a year at 80% of commercial laboratories, 62.5% of
blood centres, 27.6% of hospitals or clinics, and 8.8% of pub-
lic health centres (Table 4).
HIV testing procedures
HIV testing laboratories that implemented ‘grey zones’ (com-
prising specimens that gave a result approaching but below
the cut-off value for positivity) most often were blood
centres, followed by commercial laboratories, hospitals or
clinics, and public health centres; 32.4% of the grey zone
ranges were within 5% of the cut-off and 58.3% were within
10%. Most (77.8%) grey-zone samples were tested again by
the same person and with the same kit (Table 5). Nearly all
participants (97%) retested an HIV-positive result using the
same sample again. Most positive samples were sent to a
confirmatory institute; 84% of laboratories referred the sam-
ple to a confirmatory institute and kept the original sample
in their laboratory for ‡1 day. The most common way of
transporting samples (71.8%) was direct delivery by staff.
A positive test result was seldom reported directly to the
client or patient; only 5.7% of clients received a positive result
directly, and in most cases the physicians received the results
immediately after the screening or confirmatory tests.
Discussion
To provide reliable test results, HIV testing laboratories
should participate in a QA system that covers discipline,
management, personnel, equipment, standard operating pro-
cedures, IQC, and external quality assessment [9].
HIV testing laboratories participate in domestic or interna-
tional HIV EQAS programmes to enhance and maintain their
testing capacities. The US CDC and Australia’s National
Serology Reference Laboratory conduct international HIV
EQAS programmes dedicated solely to HIV testing [10,11].
According to the national HIV policies in the USA and Aus-
tralia, HIV testing should be carried out by HIV testing labo-
ratories only if they meet certain standards [12,13]. The
CDC Model Performance Evaluation Program (MPEP) evalu-
ates the annual performance of laboratories using an HIV
RT, and this programme includes an HIV-related question-
naire for programme participants. The MPEP provides data
about the current status and practices of HIV testing labora-
TABLE 2. Characteristics of HIV testing personnel and quality assurance programmes for HIV screening laboratories (2006)
Items
Public health
centres (n = 233)
Hospital/clinic
labs (n = 309)
Blood
centres (n = 8)
Commercial
laboratoriesa (n = 11)
Personnel status
Number of medical technologists (%) 232 (99.6%) 305 (98.7%) 8 (100%) 11 (100%)
Period of service (years) 7.7 ± 5.47 5.0 ± 4.15 3.0 ± 1.20 3.7 ± 2.61
Period of job rotation (years) 4.1 ± 2.26 2.7 ± 1.85 3.5 ± 1.69 1.9 ± 1.04
Participation in on-the-job training (%)b 168 (72.1%) 140 (45.3%) 8 (100%) 9 (81.8%)
Participation in quality assurance educationc 127 (54.5%) 123 (39.8%) 8 (100%) 5 (45.5%)
EQAS by
KCDC (KNIH) 233 (100%) 309 (100%) 8 (100%) 11 (100%)
KAQACL 27 (11.6%) 279 (90.3%) 8 (100%) 11 (100%)
CAP in USA – 6 (1.9%) – 4 (36.4%)
Blood Research Institute – – 7 (87.5%) –
Acquisition of certification
Yesd 0 227 (73.5%) 6 (75%) 11 (100%)
No 233 (100%) 82 (26.5%) 2 (25%) –
Certified (or accredited) by
KSLM – 227 (73.5%) 4 (50%) 11 (100%)
CAP in USA – 6 (1.9%) – 4 (36.4%)
ISO9000 – – 1 (12.5%) –
ISO9002 – 4 (1.3%) 4 (50%) –
KCDC, Korea Centres for Disease Control and Prevention; KNIH, Korea National Institute of Health; KAQACL, The Korean Association of Quality Assurance for Clinical Laboratory;
KSLM, The Korean Society for Laboratory Medicine; CAP, College of American Pathologists; EQAS, external quality assurance scheme.
aCommercial laboratory: commercial clinical laboratories.
bOn-the-job training: HIV-related theory or practice education.
cQuality assurance education: HIV-related quality control or EQAS education.
dSome laboratories participated in more than one programme out of four programmes
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tories internationally and includes information about person-
nel, testing sites, facility types, testing kits, HIV testing
algorithm, quality control, EQAS, and certification or accredi-
tation programmes [14]. Our survey results provide compre-
hensive information on the HIV testing laboratories in
Korea, and will enhance the existing HIV policies and prac-
tices in our country.
The personnel responsible for HIV testing was rotated
more frequently in the laboratories of hospitals and clinics
than in other testing facilities; the average duration of work-
ing in a testing laboratory in hospitals and clinics ranged from
6 months to 3 years. Because the diagnostic kits, testing
methods and QA processes change faster for HIV tests than
for other tests, staff need to update their knowledge by
regularly attending training courses and programmes. Staff at
blood centres participated in more HIV-related training
programmes than personnel at any other institution. Staff
from other institutions should be provided with more
opportunities for regular training in up-to-date testing pro-
grammes.
In Korea, the diagnostic laboratories in hospitals must
participate in the Laboratory Inspection and Accreditation
Program from the KSLM with, every 1 or 2 years, laboratory
visits by medical assessors. Public health centres also are
accredited by LIHEs after site inspections. Many HIV labora-
tories are involved in diverse EQAS and laboratory certifica-
tion or accreditation programmes to enhance their quality
management.
More public health centres used outdated equipment than
did other medical centres. Public health centres that perform
few HIV tests have adopted the PA test or RT, which
do not require any testing device. Most of the automated
TABLE 3. HIV testing equipment used by HIV screening laboratories (2006)
Automation Manufacturer Equipment name
Public health
centres
(n = 233)
Hospital/clinic
laboratories
(n = 309)
Blood
centres
(n = 8)
Commercial
laboratories
(n = 11)
Number of
laboratories
(%)a
Rate of
sample
process (%)b
Auto ABBOT AXSYM 12 87 – – 99 (23.80) 8.35
ARCHITECT – 43 – 1 44 (10.58) 13.06
IMX – 7 – – 7 (1.68) 0.21
Auto BAYER ADVIA CENTAUR – 19 – – 19 (4.67) 3.89
Auto Beckman coulter Access 14 1 – – 15 (3.61) 0.6
Auto Biomerieux VIDAS 13 2 – 1 16 (3.85) 1.9
Mini VIDAS 4 1 – – 5 (1.20) 0.05
Auto Biorad EVOLIS – 3 – 1 4 (0.96) 2.35
CODA 2 14 – 1 17 (4.09) 2.31
Auto Chemilla Labotech 6 – – – 6 (1.44) 0.23
Auto Dade Behring BEP2000 1 3 – – 4 (0.96) 0.49
Auto DSX Dynex 7 1 1 – 9 (2.16) 1.02
Auto Dynatech Dynatech MR-7000 3 – – – 3 (0.72) 0.11
Auto DIAS 3 – – – 3 (0.72) 0.07
Auto Ortho Vitros-Eci 13 8 – – 21 (5.05) 1.38
Auto Roche MODULAR E170 – 14 – – 14 (3.37) 2.52
Elecsys 2010 5 19 – – 24 (5.77) 1.09
COBAS-Core – 2 – – 2 (0.48) 0.04
Auto Rosys Plato 3300 23 – – – 23 (5.53) 0.32
Auto SEAC ALISEI 3 3 – 5 11 (2.64) 7.47
Brio 1 3 – – 4 (0.96) 1.39
ARIO 1 – – – 1 (0.24) 0.04
Semi auto Dade Behring BEP II 13 – – – 13 (3.13) 0.39
BEP II 9 4 – – 13 (3.13) 1.74
Semi auto Biotek EL808 1 – – – 1 (0.24) 0.02
Semi auto TECAN SLT-TECAN – – 7 – 7 (1.68) 45.41
Semi auto Rosys Plato 1300 16 – – – 16 (3.85) 1.03
Manual Molecular device Versamax microplate reader – 1 – – 1 (0.24) 0.22
Other manufacturers other equipments 9 4 – 1 14 (3.37) 2.32
Total (%) 159 239 8 10 416 (100) 100
aNumber of laboratories (%): the number of laboratories using the target equipment.
bRate of sample process (%): percentage of samples processed by the target equipment for all HIV tests performed in all institutions.
TABLE 4. Maintenance schedule of
testing equipment in HIV screening
laboratories (2006)
Items
No. (%) public
health centres
No. (%) hospital
or clinic labs
No. (%) blood
centres
No. (%)
commercial
laboratories
Periodic check-up service (per year) 38 (23.9) 119 (49.8) 7 (87.5) 9 (90)
Once 14 (8.8) 22 (9.2) 1 (12.5) 0 (0)
Twice 10 (6.3) 31 (13.0) 1 (12.5) 1 (10)
Three times 14 (8.8) 66 (27.6) 5 (62.5) 8 (80)
Service for troubleshooting only 121 (76.1) 120 (50.2) 1 (12.5) 1 (10)
Total (%) 159 (100) 239 (100) 8 (100) 10 (100)
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diagnostic equipment currently in use is produced by a few
large suppliers such as Abbot and Roche. There were no
regular maintenance schedules for the equipment in some
laboratories, and >50% of laboratories serviced the equip-
ment only when it malfunctioned.
Blood centres set the ‘grey zone’ at a wider cut-off (>10%)
to provide a safe blood supply. HIV-positive screening samples
should be referred to LIHEs to confirm the test results. In
practice, 30% of hospitals/clinics referred their reactive
samples to public health centres or commercial laboratories
for supplementary tests, which consumed additional time.
Greater attention is needed to ensure the safe transport
of samples sent for confirmation. Korea adopts the standard-
ized procedures the WHO set forth in its Introduction to the
transport of infectious substances manual [15,16]. Overall, 87%
of samples for final HIV confirmation were delivered by
either personal service directly from the testing site or
through a commercial laboratory and 13% were delivered by
door-to-door and postal services. It is imperative to imple-
ment the international standards for transporting such sam-
ples to ensure safety.
There are some limitations to this study. First, we
excluded detailed questions about the use of external quality
control in this survey analysis, defining external QC as any
other controls included in the test run that involved inde-
pendent (separate) control of a kit’s components. More than
45% of private institutions interpreted this to mean the use
of internal control of a kit’s components. This reflected a dif-
ference between public and private institutions, indicating the
need to standardize the terminologies in future surveys. Sec-
ond, answers to the questionnaire might differ from the
actual performance of HIV testing because they were not
confirmed by site inspection, although about 50 randomly
selected HIV testing laboratories were interviewed by the
HIV experts to confirm the survey response.
However, this is the first survey in Korea to focus on the per-
sonnel, equipment, environment, test kits, testing procedures,
and quality assessment of HIV testing laboratories. Our data
show a need for education by expanding training opportunities
for HIV testers, regular maintenance of equipment, and devel-
opment of a system to transport infectious substances safely.
The results of this survey will be used in formulating a system-
TABLE 5. Management strategies for preliminary positive cases in HIV screening tests (2006)
Items
Public health
centres
n = 233 n (%)
Hospital/clinic
laboratories
n = 309 n (%)
Blood
centres
n = 8 n (%)
Commercial
laboratories
n = 11 n (%)
‘Grey zone’ setting institutes 68 (29.2) 133 (43.0) 8 (100) 8 (72.7)
The range of ‘grey zone’
Cut-off within 5% 23 (33.8) 46 (34.6) – 1 (12.5)
Cut-off within 10% 43 (63.2) 76 (57.1) 2 (25.0) 5 (62.5)
Cut-off within 20% 1 (1.5) 5 (3.8) 4 (50.0) –
Other 1 (1.5) 6 (4.5) 2 (25.0) 2 (25.0)
Test method for ‘grey zone’ sample
With the same test kit by the same person 43 (63.2) 115 (86.5) 5 (62.5) 5 (62.5)
With another lot of the same test kit by the same person 6 (8.8) 5 (3.8) – –
With the same test kit by a different person – 2 (1.5) 3 (37.5) 2 (25.0)
Other 19 (27.9) 11 (8.3) – 1 (12.5)
Sample retested
Yes 219 (94.0) 306 (99.0) 8 (100) 11 (100)
No 14 (6.0) 3 (1.0) – –
Retest with same sample
With the same lot of the same test kit 179 (81.7) 251 (82.0) 7 (87.5) 10 (90.9)
With another lot of the same test kit 3 (1.4) – – –
With a different kind of test kit (another assay) 20 (9.1) 8 (2.6) – –
By another person 1 (0.5) 2 (0.7) – –
Retest with re-sample 16 (7.3) 45 (14.7) 1 (1.25) 1 (9.1)
Referral institutes for HIV confirmation
Local institute of health and environment 229 (98.3) 157 (50.8) 1 (12.5) 8 (72.7)
Public health centre – 95 (30.7) – –
KCDC 3 (1.3) 22 (7.1) 1 (12.5) 1 (9.1)
Blood Research Institute – – 6 (75.0) –
Commercial laboratory – 34 (11.0) – 1 (9.1)
Other 1 (0.4) 1 (0.3) – 1 (9.1)
Deposit on referral sample
Deposit 162 (69.5) 291 (94.2) 7 (87.5) 11 (100)
No deposit 71 (30.5) 18 (5.8) 1 (12.5) –
Sample conveyance for confirmatory testing
Personnel service directly from testing sites 185 (73.4) 204 (66.0) 3 (37.5) 11 (100)
Personnel service through commercial laboratories – 85 (27.5) – –
Postal service (registered) 17 (7.3) 5 (1.6) – –
Door-to-door service (immediately) 2 (0.9) 15 (4.9) – –
Door-to-door service (via company) 29 (12.4) – 5 (62.5) –
Report of the test result in an HIV testing laboratory
Provide the screening result to the doctor (medical team) 62 (26.6) 231 (74.8) 1 (12.5) 9 (81.8)
Provide the confirmatory result to the doctor 136 (58.4) 76 (24.6) 6 (75.0) 2 (8.2)
Provide the result to the patient directly 32 (13.7) – – –
Other 3 (1.3) 2 (0.6) 1 (12.5) –
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atic and effective policy, and will serve as reference data for
improving the quality of HIV testing in Korea.
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